Rasio cepet Orgenesis Inc (ORGS)

The market trend for Orgenesis Inc. (ORGS) shown on this price chart reflects the dynamics of a company with strong pricing power driven by customer lock-in to its IT solutions, while the liquidity ratio stands at 0.07. The business relies on a global network of local centers that produce biologics directly within clinics. The development of a decentralized system by 2026 will allow for a significant reduction in transportation costs for complex gene products.

The distributed R&D model of Orgenesis Inc. (ORGS) requires high capital mobility to support innovative biotechnological developments. This metric assesses solvency by considering only cash and accounts receivable, completely excluding low-liquidity inventories. For the investor, this is a critical marker of financial stability and the company's ability to promptly cover short-term liabilities. The dynamics of the quick ratio provide an objective assessment of the quality of treasury management.